title: Open-label, phase I, pharmacokinetic studies of abiraterone acetate in healthy men.
abstract: OBJECTIVE
  To evaluate pharmacokinetics, safety, and tolerability of abiraterone acetate (AA) in healthy men.
  
  
  METHODS
  Two phase I studies (dose-escalation study and dose-proportionality study) were conducted in healthy men aged 18-55 years. All subjects received 4 consecutive single doses of AA (250, 500, 750 and 1,000 mg). The dose-escalation study subjects (N = 33) received AA doses in a sequential manner, starting with the lowest dose. The dose-proportionality study subjects (N = 32) were randomly allocated (1:1:1:1) to receive each of the 4 doses in a four-way crossover design.
  
  
  RESULTS
  A dose-related increase in abiraterone exposure was observed in both studies. Over the evaluated dose range, the mean abiraterone maximum plasma concentrations increased from 26 to 112 ng/mL in dose-escalation study and from 40 to 125 ng/mL in dose-proportionality study; the mean area under the plasma concentration-time curve from 0 to the last measurable plasma concentration increased from 155 to 610 ng.h/mL in dose-escalation study, and from 195 to 607 ng.h/mL in dose-proportionality study. In the dose-proportionality study, abiraterone exposure was dose proportional between 1,000 and 750 mg doses; however, the exposure was slightly greater than dose proportional when exposures at 500 and 250 mg doses were compared with the exposure at 1,000 mg. Single doses of AA were well tolerated in healthy men, and safety profile was consistent with its known toxicities in CRPC patients.
  
  
  CONCLUSIONS
  Systemic exposure to abiraterone increased with increasing doses of AA (250-1,000 mg) in healthy men; AA was well tolerated in this population.
authors.affiliation: Janssen Research and Development, LLC, 920 Route 202 South, Raritan, NJ 08869, USA. macharya@its.jnj.com
authors.forename: M
authors.initials: M
authors.lastname: Acharya
authors.forename: A
authors.initials: A
authors.lastname: Bernard
authors.forename: M
authors.initials: M
authors.lastname: Gonzalez
authors.forename: J
authors.initials: J
authors.lastname: Jiao
authors.forename: R
authors.initials: R
authors.lastname: De Vries
authors.forename: N
authors.initials: N
authors.lastname: Tran
mesh_terms: D000293:Adolescent; D000328:Adult; D000736:Androstenes; D000737:Androstenols / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008875:Middle Aged; D013739:Testosterone / Q000097:blood
chemical_list: D000736:Androstenes; D000737:Androstenols; D013739:Testosterone; D007986:Luteinizing Hormone; C089740:abiraterone